---
title: 'Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated
  with Idecabtagene Vicleucel: The U.S. Myeloma Immunotherapy Consortium Real World
  Experience'
date: '2024-06-04'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38834151/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240605181401&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: Our findings indicate that low pre-LD ALC with high percent
  reduction from pre-A to pre-LD was associated with inferior survival outcomes, particularly
  OS, in patients who received SOC ...'
disable_comments: true
---
CONCLUSION: Our findings indicate that low pre-LD ALC with high percent reduction from pre-A to pre-LD was associated with inferior survival outcomes, particularly OS, in patients who received SOC ...